

ROUTING FORM

Job #: _____

Patient Facing Materials
(requires Euro Legal Review)

Client: _____ Product: _____

Description: _____

First Mechanical

Final Mechanical


Client Comments Received/Transcribed Date: _____ Initials: _____

Operator: _____ Extension: _____ Date: _____ Time: _____

PM: _____ Extension: _____ ArtDir: _____ Extension: _____

SIGN-OFF	INITIALS	DATE	TIME	COMMENTS
Art Director	REVISED 3:14 pm, Jan 07, 2021			<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Art Supervisor				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Editor				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Editor 2—Double Read <input type="checkbox"/>				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Copywriter				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Copy Supervisor				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Creative Director Art				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Creative Director Copy				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Assoc. Creative Director				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Account Executive				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Account Supervisor				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Acct. Group Supervisor				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Sr. Mgmt. Supervisor				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Medical Director				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Production				<input type="checkbox"/> OK <input type="checkbox"/> Corrections
Art Buyer				<input type="checkbox"/> OK <input type="checkbox"/> Corrections

NOTES



For the treatment of postmenopausal women with osteoporosis at high risk for fracture.

EVENITY® for 12 months followed by alendronate provided superior vertebral and nonvertebral fracture risk reduction vs alendronate alone¹



INDICATION

EVENITY® is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.

The anabolic effect of EVENITY® wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY® use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered.

IMPORTANT SAFETY INFORMATION

POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH



EVENITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY® should be discontinued.

Please scroll below for additional Important Safety Information.


Dear [Insert Customer Name],

The ARCH Study was a Phase 3, head-to-head, randomized, double-blind, alendronate-controlled study comparing EVENITY® followed by alendronate vs alendronate alone in 4,093 postmenopausal women with osteoporosis who have experienced a fracture. Co-primary endpoints were incidence of morphometric vertebral fracture at 24 months and time to first clinical fracture (nonvertebral and symptomatic vertebral fracture) through the primary analysis period.^{1,2}

EVENITY® was compared to a commonly prescribed antiresorptive²



EVENITY® followed by alendronate reduced nonvertebral fracture risk^{1,2}



- VARIABLE SUBJECT LINE OPTIONS:**
1. [Fracture Risk Reduction Results]
 2. [Reduced Fracture Incidence]
 3. [Significant Reduction of Fracture Incidence]
 4. [Significant Reduction of New Fracture]

Adverse Reactions Occurring in $\geq 2\%$ of EVENITY®-Treated Women in Double-blind Portion of the ARCH Trial^{1,††}

Preferred Term	Alendronate (N=2014) n (%)	EVENITY® (N=2040) n (%)
Arthralgia	194 (9.6)	166 (8.1)
Headache	110 (5.5)	106 (5.2)
Muscle spasms	81 (4.0)	70 (3.4)
Edema peripheral	38 (1.9)	34 (1.7)
Asthenia	53 (2.6)	50 (2.5)
Neck pain	42 (2.1)	34 (1.7)
Insomnia	36 (1.8)	34 (1.7)
Parosmia	34 (1.7)	29 (1.4)

[†]Adverse reactions based on occurrence in $\geq 2\%$ of EVENITY®-treated patients in either FRAME or ARCH and a plausible relationship to EVENITY®.

Major Adverse Cardiac Events (MACE)^{†††}

During the 12-month double-blind treatment period of the active-controlled trial (ARCH):

- Myocardial infarction^{§§} occurred in 16 women (0.8%) in the EVENITY® group and 5 women (0.2%) in the alendronate group
- Stroke^{§§} occurred in 13 women (0.6%) in the EVENITY® group and 7 women (0.3%) in the alendronate group
- Cardiovascular death^{***} occurred in 17 women (0.8%) in the EVENITY® group and 12 women (0.6%) in the alendronate group
- MACE resulted in incidences of 41 (2.0%) in the EVENITY® group and 22 (1.1%) in the alendronate group
- ARCH MACE Hazard Ratio: 1.87 (1.11, 3.14) for EVENITY® compared to alendronate

^{§§}MACE is a composite endpoint of positively adjudicated myocardial infarction, stroke, and cardiovascular death.

^{†††}These events occurred in patients with and without a history of myocardial infarction or stroke.

^{***}Includes fatal events adjudicated as CV-related or undetermined.

^{§§§}CV=cardiovascular; MI=myocardial infarction.

Consider EVENITY® first after fracture when your members' risk of another is at its highest.^{1,3}

Please visit EVENITYHCP.com for more information.

IMPORTANT SAFETY INFORMATION

POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH

EVENITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY® should be discontinued.

In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, in patients treated with EVENITY® compared to those treated with alendronate.

Contraindications: EVENITY® is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating therapy with EVENITY®. EVENITY® is contraindicated in patients with a history of systemic hypersensitivity to romosozumab or to any component of the product formulation. Reactions have included angioedema, erythema multiforme, and urticaria.

Hypersensitivity: Hypersensitivity reactions, including angioedema, erythema multiforme, dermatitis, rash, and urticaria have occurred in EVENITY®-treated patients. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of EVENITY®.

Hypocalcemia: Hypocalcemia has occurred in patients receiving EVENITY®. Correct hypocalcemia prior to initiating EVENITY®. Monitor patients for signs and symptoms of hypocalcemia, particularly in patients with severe renal impairment or receiving dialysis. Adequately supplement patients with calcium and vitamin D while on EVENITY®.

Osteonecrosis of the Jaw (ONJ): ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving EVENITY®. A routine oral exam should be performed by the prescriber prior to initiation of EVENITY®. Concomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase the risk of developing ONJ. Other risk factors for ONJ include cancer, radiotherapy, poor oral hygiene, pre-existing dental disease or infection, anemia, and coagulopathy.

For patients requiring invasive dental procedures, clinical judgment should guide the management plan of each patient. Patients who are suspected of having or who develop ONJ should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of EVENITY® should be considered based on benefit-risk assessment.

Atypical Femoral Fractures: Atypical low-energy or low trauma fractures of the femoral shaft have been reported in patients receiving EVENITY®. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated.

During EVENITY® treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be evaluated to rule out an incomplete femur fracture. Interruption of EVENITY® therapy should be considered based on benefit-risk assessment.

Adverse Reactions: The most common adverse reactions ($\geq 5\%$) reported with EVENITY® were arthralgia and headache.

EVENITY® is a humanized monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity.

Please see EVENITY® full [Prescribing Information](#), including [Medication Guide](#).

References:

1. EVENITY® (romosozumab-aqqg) prescribing information, Amgen.
2. Saag KG, Petersen J, Brandt ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med*. 2017;377:1417-1427.
3. van Geel TACM, van Helden S, Geusens PP, Winkens B, Dinant G-J. Clinical subsequent fractures cluster in time after first fractures. *Ann Rheum Dis*. 2009;68:99-102.

Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com
© 2020 Amgen Inc. All rights reserved.
USA-785-81480 11/20

AMGEN®

[Privacy Statement](#) | [Terms of Use](#) | [Contact Us](#)


You received this e-mail because you are a customer of Managed Healthcare Executive, a M&H Life Sciences publication. You are on the mailing list as SUSER@SDOMAIN

To ensure delivery to your inbox, please add us to your address book.

From time to time, we will inform customers of latest offers and new products from relevant business partners. If you do not wish to receive this type of information, [click here](#).

Contact us via email at rmhinfo@mmhgroup.com or contact us by mail at

M&H Life Sciences
Attn: Subscriptions
2 Clarke Drive, Ste 100
Craneburg, NJ 08512
USA
[Privacy Policy](#)



For the treatment of postmenopausal women with osteoporosis at high risk for fracture.

EVENITY® for 12 months followed by alendronate provided superior vertebral and nonvertebral fracture risk reduction vs alendronate alone¹



INDICATION

EVENITY® is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. The anabolic effect of EVENITY® wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY® use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an antiresorptive agent should be considered.

**IMPORTANT SAFETY INFORMATION
POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH**

EVENITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY® should be discontinued.


Please scroll below for additional Important Safety Information.

Dear [Insert Customer Name],


The ARCH Study was a Phase 3, head-to-head, randomized, double-blind, alendronate-controlled study comparing EVENITY® followed by alendronate vs alendronate alone in 4,093 postmenopausal women with osteoporosis who have experienced a fracture. Co-primary endpoints were incidence of morphometric vertebral fracture at 24 months and time to first clinical fracture (nonvertebral and symptomatic vertebral fracture) through the primary analysis period.^{1,2}

EVENITY® was compared to a commonly prescribed antiresorptive²

- VARIABLE SUBJECT LINE OPTIONS:**
- [Fracture Risk Reduction Results]
 - [Reduced Fracture Incidence]
 - [Significant Reduction of Fracture Incidence]
 - [Significant Reduction of New Fracture]




The study population consisted of postmenopausal women (55-90 years old). All of the study participants had a bone mineral density (BMD) T-score ≤ -2.5 at the total hip or femoral neck and either one moderate or severe vertebral fracture or two mild vertebral fractures, or BMD T-score ≤ -2.0 at the total hip or femoral neck, and either two moderate or severe vertebral fractures or a history of proximal femur fracture. All women were supplemented with daily calcium and vitamin D.¹
PO=orally; QM=monthly; QW=weekly; SC=subcutaneous.



EVENITY® for 12 months followed by alendronate reduced the incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at primary analysis (median 33 months) ($P < 0.001$).¹
This was an event-driven trial and the duration of follow-up varied across subjects. The median duration of subject follow-up for the primary analysis period was 33 months.
¹Absolute and relative risk reductions are based on the Mantel-Haenszel method adjusting for age strata, baseline total hip BMD T-score (≤ -2.5 , > -2.5), and presence of severe vertebral fracture at baseline.
²P value based on logistic regression model (new vertebral fracture) or Cox proportional hazards model (other fracture types) adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
³Nonvertebral fractures excluded fractures of the skull, facial bones, metacarpals, fingers, and toes. Pathologic or high trauma fractures were also excluded.
ARR=absolute risk reduction.

EVENITY® followed by alendronate reduced nonvertebral fracture risk^{1,2}



This was an event-driven trial and the duration of follow-up varied across subjects. The median duration of subject follow-up for the primary analysis period was 33 months.

¹Secondary endpoint.
²Hazard ratio/relative risk reduction and P value are based on Cox proportional hazards model adjusting for age strata, baseline total hip BMD T-score, and presence of severe vertebral fracture at baseline.
ARR=absolute risk reduction; BMD=bone mineral density; RRR=relative risk ratio.

Adverse Reactions Occurring in $\geq 2\%$ of EVENITY®-Treated Women in Double-blind Portion of the ARCH Trial^{1,††}

Preferred Term	Alendronate (N=2014) n (%)	EVENITY® (N=2040) n (%)
Arthralgia	194 (9.6)	166 (8.1)
Headache	110 (5.5)	106 (5.2)
Muscle spasms	81 (4.0)	70 (3.4)
Edema peripheral	38 (1.9)	34 (1.7)
Asthenia	53 (2.6)	50 (2.5)
Neck pain	42 (2.1)	34(1.7)
Insomnia	36 (1.8)	34(1.7)
Parosmia	34 (1.7)	29 (1.4)

^{††}Adverse reactions based on occurrence in $\geq 2\%$ of EVENITY®-treated patients in either FRAME or ARCH and a plausible relationship to EVENITY®.

Major Adverse Cardiac Events (MACE)^{1,††}

During the 12-month double-blind treatment period of the active-controlled trial (ARCH):

- Myocardial infarction^{§§} occurred in 16 women (0.8%) in the EVENITY® group and 5 women (0.2%) in the alendronate group
- Stroke^{†††} occurred in 13 women (0.6%) in the EVENITY® group and 7 women (0.3%) in the alendronate group
- Cardiovascular death^{***} occurred in 17 women (0.8%) in the EVENITY® group and 12 women (0.6%) in the alendronate group
- MACE resulted in incidences of 41 (2.0%) in the EVENITY® group and 22 (1.1%) in the alendronate group
- ARCH MACE Hazard Ratio: 1.87 (1.11, 3.14) for EVENITY® compared to alendronate

¹MACE is a composite endpoint of positively adjudicated myocardial infarction, stroke, and cardiovascular death.
^{††}These events occurred in patients with and without a history of myocardial infarction or stroke.
^{***}Includes fatal events adjudicated as CV-related or undetermined. CV=cardiovascular; MI=myocardial infarction.

Consider EVENITY® first after fracture when your members' risk of another is at its highest.^{1,3}
Please visit EVENITYHCP.com for more information.

**IMPORTANT SAFETY INFORMATION
POTENTIAL RISK OF MYOCARDIAL INFARCTION, STROKE, AND CARDIOVASCULAR DEATH**
EVENITY® may increase the risk of myocardial infarction, stroke and cardiovascular death. EVENITY® should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. Consider whether the benefits outweigh the risks in patients with other cardiovascular risk factors. Monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur. If a patient experiences a myocardial infarction or stroke during therapy, EVENITY® should be discontinued.

In a randomized controlled trial in postmenopausal women, there was a higher rate of major adverse cardiac events (MACE), a composite endpoint of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke, in patients treated with EVENITY® compared to those treated with alendronate.

Contraindications: EVENITY® is contraindicated in patients with hypocalcemia. Pre-existing hypocalcemia must be corrected prior to initiating therapy with EVENITY®. EVENITY® is contraindicated in patients with a history of systemic hypersensitivity to romosozumab or to any component of the product formulation. Reactions have included angioedema, erythema multiforme, and urticaria.

Hypersensitivity: Hypersensitivity reactions, including angioedema, erythema multiforme, dermatitis, rash, and urticaria have occurred in EVENITY®-treated patients. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of EVENITY®.

Hypocalcemia: Hypocalcemia has occurred in patients receiving EVENITY®. Correct hypocalcemia prior to initiating EVENITY®. Monitor patients for signs and symptoms of hypocalcemia, particularly in patients with severe renal impairment or receiving dialysis. Adequately supplement patients with calcium and vitamin D while on EVENITY®.

Osteonecrosis of the Jaw (ONJ): ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients receiving EVENITY®. A routine oral exam should be performed by the prescriber prior to initiation of EVENITY®. Concomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase the risk of developing ONJ. Other risk factors for ONJ include cancer, radiotherapy, poor oral hygiene, pre-existing dental disease or infection, anemia, and coagulopathy.

For patients requiring invasive dental procedures, clinical judgment should guide the management plan of each patient. Patients who are suspected of having or who develop ONJ should receive care by a dentist or an oral surgeon. In these patients, dental surgery to treat ONJ may exacerbate the condition. Discontinuation of EVENITY® should be considered based on benefit-risk assessment.

Atypical Femoral Fractures: Atypical low-energy or low trauma fractures of the femoral shaft have been reported in patients receiving EVENITY®. Causality has not been established as these fractures also occur in osteoporotic patients who have not been treated.

During EVENITY® treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be evaluated to rule out an incomplete femur fracture. Interruption of EVENITY® therapy should be considered based on benefit-risk assessment.

Adverse Reactions: The most common adverse reactions ($\geq 5\%$) reported with EVENITY® were arthralgia and headache.

EVENITY® is a humanized monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity.

Please see EVENITY® full Prescribing Information, including Medication Guide.

References:
1. EVENITY® (romosozumab-aqqg) prescribing information, Amgen. 2. Saag KG, Petersen J, Brandt ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med.* 2017;377:1417-1427. 3. van Geel TACM, van Helden S, Geusens PP, Winkens B, Dinant G-J. Clinical subsequent fractures cluster in time after first fractures. *Ann Rheum Dis.* 2009;68:99-102.



Privacy Statement | Terms of Use | Contact Us

You received this e-mail because you are a customer of Managed Healthcare Executive, a MJH Life Sciences publication. You are on the mailing list as SUSER@DOMAIN

To ensure delivery to your Inbox, please add us to your address book.

From time to time, we will inform customers of latest offers and new products from relevant business partners. If you do not wish to receive this type of information, [click here](#).

Contact us via email at rmhinfo@mhgroup.com or contact us by mail at

MJH Life Sciences
Attn: Subscriptions
2 Clarke Drive, Ste 100
Crabtree, NJ 08512
USA
[Privacy Policy](#)